Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7 to 267.43) to 191.4 RU/mL (IQR 132.6 to 316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Single-blind reported · Human research reported
Reported blinded roles: participants.
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This was a single-blind pilot study.
Source: Abstract.
Participants were blinded to treatment status and investigators were not.
Source: Methods.
Participants were blinded to treatment status and investigators were not.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study
Study design awaiting verification · BMC Nephrology · 2016
Original publication title
Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study
© The Author(s). 2016
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD.
Source: BackgroundAbstract: What methods does the paper describe?
This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15 to 45 mL/min/1.73 m2 and serum bicarbonate between 20 to 24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate.
Source: MethodsAbstract: Results
After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7 to 267.43) to 191.4 RU/mL (IQR 132.6 to 316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D.
Source: ResultsAbstract: Conclusions
FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors.
Source: ConclusionsAuthors’ abstract
Background
The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD.
Methods
This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15 to 45 mL/min/1.73 m2 and serum bicarbonate between 20 to 24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate.
Results
After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7 to 267.43) to 191.4 RU/mL (IQR 132.6 to 316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D.
Conclusions
FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors.
Trial registration
The study was registered at ClinicalTrials.gov (NCT00888290) on April 23, 2009.
Publication and source details
Original title: Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study
Wei Chen; Michal L. Melamed; Thomas H. Hostetter; Carolyn Bauer; Amanda C. Raff; Anthony L. Almudevar; Amy Lalonde; Susan Messing; Matthew K. Abramowitz
BMC Nephrology · 2016
© The Author(s). 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/100000002National Institutes of HealthDK020541K23 DK099438Abramowitz Matthew K. http://dx.doi.org/10.13039/100000097National Center for Research Resources1 UL1 RR024160-011 UL1 RR024160-01Lalonde Amy Messing Susan Renal Research InstituteResearch GrantChen Wei http://dx.doi.org/10.13039/100001463american society of nephrologyCarl W. Gottschalk Research Scholar GrantAbramowitz Matthew K.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T09:11:02.748063+00:00
DOI: 10.1186/s12882-016-0331-6 · PMC4974735